Abstract
One of the newest agents used in the treatment of breast cancer is trastuzumab (Herceptin®), a new recombinant DNA-derived humanized monoclonal antibody against the proto-oncogene, HER-2/neu gene product. However, despite its proven clinical efficacy, serious adverse effects leading to trastuzumab-induced cardiomyopathy have been described in up to 27% of patients receiving combination therapy with anthracyclines [1]. There has been little published on the clinical syndrome of trastuzumab-induced cardiomyopathy. We describe three cases, of both reversible and irreversible cardiomyopathy, associated with the use of this novel and effective agent in HER-2 overexpressing breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a mono-clonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792, 2001
Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17: 2235–2249, 1998
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989
Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of Her.2/neu oncogene ampli-fication in primary breast cancer. J Clin Oncol 11: 1936–1942, 1993
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648, 1999
Ewer MS, Gibbs HR, Swafford J, Benjamin RS: Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26 (suppl 12): 96–101, 1999
Hudis C, Seidman A, Paton V, Bednarski D, Ashby M, Keefe D: Characterization of cardiac dysfunction in the Herceptin clinical trials. Breast Cancer Res Treat 62 (abstr 24): 24, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tham, YL., Verani, M.S. & Chang, J. Reversible and Irreversible Cardiac Dysfunction Associated with Trastuzumab in Breast Cancer. Breast Cancer Res Treat 74, 131–134 (2002). https://doi.org/10.1023/A:1016140729725
Issue Date:
DOI: https://doi.org/10.1023/A:1016140729725